Increased vascular α1-adrenergic sensitivity in patients with renal failure: Receiving recombinant erythropoeitin

American Journal of Therapeutics

Volumn 14, Issue 5, 2007, Pages 427-434

  Abiose, Ademola K ^a   Aronow, Wilbert S ^b   Moreno Jr , Heitor ^c   Nair, Chandra K ^d   Blaschke, Terrence F ^e,f   Hoffman, Brian B ^e,f  

^a UNIVERSITY OF IOWA   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF CAMPINAS   (Brazil)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

1 adrenergic sensitivity; End stage renal disease; Endothelial function; Hemodialysis; Recombinant erythropoietin; Vascular responsiveness

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BRADYKININ; NITRIC OXIDE; PHENYLEPHRINE; RECOMBINANT ERYTHROPOIETIN; ALPHA 1 ADRENERGIC RECEPTOR; VASOCONSTRICTOR AGENT; VASODILATOR AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG MECHANISM; ENDOTHELIUM; FEMALE; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VASCULAR RESISTANCE; VASODILATATION; VEIN DILATATION; VENOCONSTRICTION; VOLUNTEER; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; HAND; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; VEIN;

ADULT; BRADYKININ; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HAND; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE; PHENYLEPHRINE; RECEPTORS, ADRENERGIC, ALPHA-1; RENAL DIALYSIS; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS; VEINS;

EID: 34748823569     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000212899.58575.33     Document Type: Article

References (32)

1. Eschbach J, Egrie J, Downing M, et al. Correction of the anemia of ESRD with recombinant human erythropoietin. Results of a combined phase I & II clinical trials. N Eng J Med. 1987;316:73-78.
2. Yamakado M, Umezu M, Nagano M, et al. Mechanism of hypertension induced by erythropoietin in patients on hemodialysis. Clin Invest Med. 1991;14:623-629.
3. Smith KJ, Bleyer AJ, Little WC, et al. The cardiovascular effects of erythropoietin. Cardiovas Res. 2003;59:538-548.
4. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis. 1991;18:76-83.
5. Vaziri ND, Zhou XJ, Smith J, et al. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol. 1995;269:F838-F845.
6. Mayer G, Horl WH. Cardiovascular effects of increasing hemoglobin in chronic renal failure. Am J Nephrol. 1996;16:263-269.
7. Heindenreich S, Rahn K-H, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 1991;39:259-265.
8. Tsukada M, Ishimitsu T, Ogawa Y, et al. Direct vasopressor effects of erythropoietin in genetically hypertensive rats. Life Sci. 1993;52:1425-1434.
9. Neusser M, Tepel M, Zidek W. Erythropoietin increases cytosolic free calcium concentration in vascular smooth muscle cells. Cardiovasc Res. 1993;27:1233-1236.
10. Bund S, Heagerty A, Edmunds M, et al. Erythropoietin does not induce vasoconstriction directly in human subcutaneous resistance arterioles. Nephron. 1989;53:173.
11. Pagel H, Jelkmann W, Weiss C. Erythropoietin and blood pressure. Horm Metab Res. 1989;21:224.
12. Lai KN, Lui SF, Leung JC, et al. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron. 1991;57:394-400.
13. Yaqoob M, Morris K, Bell G, et al. Suppression of the renin-angiotensin-aldosterone axis with erythropoietin therapy by a negative feedback loop. Nephrol Dial Transplant. 1992;7:125-128.
14. Lebel M, Kingma I, Grose JH, et al. Hemodynamic and hormonal changes during erythropoietin treatment in hemodialysis patients. J Am Soc Nephrol. 1998;9:97-104.
15. Hand M, Haynes W, Johnstone H, et al. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int. 1995;48:806-813.
16. Bode-Boger S, Boger R, Kuhn M, et al. Recombinant human erythropoietin enhance vasoconstriction tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996;50:1255-1261.
17. Zhou XJ, Pandian D, Wang XQ, et al. Erythropoietin-induced hypertension in rats is not mediated by alterations of plasma endothelin, vasopressin, or atrial natriuretic peptide levels. J Am Soc Nephrol. 1997;8:901-905.
18. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
19. Dachman W, Ford G, Blaschke T, et al. Mechanism of bradykinin-induced venodilation in humans. J Cardiovasc Pharmacol. 1993;21:241-248.
20. Calver A, Collier J, Leone A, et al. Effect of local intraarterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens. 1993;7:193-194.
21. Pan H, Hoffman B, Pershe R, et al. Decline in beta adrenergic receptor-mediated relaxation with aging in man. J Pharmacol Exp Ther. 1986;239:802-807.
22. Fleming W, Westfall D, De La Lande I, et al. Log-normal distribution of effective doses of norepinephrine and acetylcholine in several tissues. J Pharmacol Exp Ther. 1972;181:339-345.
23. Warren D, Mathias C, Naik R. Hemodynamic effects of noradrenaline and isoprenaline in chronic renal failure. Contr Nephrol. 1984;41:420-424.
24. Pan H, Hoffman B, Persche R, et al. Differences in recovery from vasoconstriction due to alpha agonists studiedwith the dorsal hand vein technique. Clin Pharmacol Ther. 1985;37:219.
25. Alradi A, Carruthers S. Evaluation and application of the linear variable differential transformer technique for the assessment of human dorsal vein alpha receptor activity. Clin Pharmacol Ther. 1985;38:495-502.
26. Bauersachs J, Popp R, Hecker M, et al. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation. 1996;94:3341-3347.
27. McCulloch AI, Bottrill FE, Randall MD, et al. Characterization and modulation of EDHF-mediated relaxations in the rat isolated superior mesenteric arterial bed. Br J Pharmacol. 1997;120:1431-1438.
28. Taddei S, Ghiadoni L, Virdis A, et al. Vasodilation to Bradykinin is mediated by an Oubain-sensitive pathway as a compensatory mechanism for impaired Nitric oxide availability in essential hypertensive patients. Circulation. 1999;100:1400-1405.
29. Quilley J, Fulton D, McGiff JC. Hyperpolarizing factors. Biochem Pharmacol. 1997;54:1059-1070.
30. Ford G, Katzir D, Blaschke T, et al. Responsiveness of peripheral veins to vasodilators and the effect of nifedipine on alpha adrenergic responsiveness in hypertension. Clin Pharmacol Ther. 1991;50:198.
31. Eichler H, Ford G, Blaschke T, et al. Responsiveness of superficial hand veins to phenylephrine in essential hypertension. J Clin Invest. 1989;83:108-112.
32. Feldman R, Freedman D, Bierbrier G, et al. Beta adrenergic responsiveness is regulated selectively in hypertension. Clin Pharmacol Ther. 1993;54:654-660.